Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epetraborole QT Interval Study in Healthy Adults
NCT05995444Phase 1Completed
- Sponsor
- AN2 Therapeutics, Inc.
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of epetraborole in Mycobacterium avium complex lung disease (4 arms), sponsored by AN2 Therapeutics, Inc. Primary endpoint: Change from baseline in heart rate corrected QT interval (QTc) at Day 2. Started Jun 2023; status: completed.
02
Drugs
epetraborole
03
Conditions
Mycobacterium avium complex lung disease
Beyond the preview
Go deeper on NCT05995444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995444.